Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series - 04/06/15
Abstract |
Hyperglycaemia may develop after whole-pancreas transplantation (PTX) in patients with type 1 diabetes mellitus (T1DM), but the efficacy and tolerability of GLP-1 receptor agonists have not been assessed in this population. This report is a 6-month prospective follow-up of six T1DM recipients of PTX (mean time after PTX: 68.8±45.7 months), all of whom had an HbA1c>6.5% (48mmol/mol) [mean: 7.1% (54mmol/mol)] after initiation of liraglutide alone at 0.6mg once daily titrated to 1.2mg once daily at week 1. Gastrointestinal disorders were reported in three of the six patients, with discontinuation of liraglutide in only one patient. HbA1c improved in the five remaining patients, with a median decrease of 0.8% (0.0–2.7%) at 6 months, and the median decrease in body weight was 2.0kg. Immunosuppressive treatments remained unchanged with liraglutide. Thus, liraglutide appears to be an effective and well-tolerated option in PTX patients with impaired glucose homoeostasis, regardless of the cause.
Le texte complet de cet article est disponible en PDF.Keywords : GLP-1 receptor agonist, Pancreas transplantation, Type 1 diabetes
Plan
Vol 41 - N° 3
P. 252-257 - juin 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.